New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 1, 2014
15:40 EDTAMGNAmgen announces Phase 2 results of Vectibix study
Amgen announced results from the Phase 2 PEAK study that reinforce the improved overall survival, OS, benefit of panitumumab, Vectibix, when used in combination with FOLFOX, an oxaliplatin-based chemotherapy regimen, compared to bevacizumab, Avastin, plus FOLFOX as first-line treatment in patients with wild-type RAS metastatic colorectal cancer, mCRC. The data was presented today at the 50th Annual Meeting of the American Society of Clinical Oncology,ASCO, in Chicago.The data presented at ASCO was an extended analysis of the PEAK study that supports the use of panitumumab in combination with FOLFOX for patients with wild-type RAS mCRC. In this exploratory analysis, patients who received panitumumab plus FOLFOX and were then treated with a VEGF inhibitor-based treatment had a median OS improvement of 41.3 months. By comparison, patients who received bevacizumab plus FOLFOX and were then treated with an anti-EGFR inhibitor-based treatment, had a median OS improvement of 29.0 months. For both arms, outcomes were similar to those observed in the overall treated population with wild-type RAS mCRC. "The initial PEAK data reinforce the potential importance of panitumumab for select patients, but we wanted to evaluate whether this benefit was dependent on administration with FOLFOX and if other subsequent treatments might impact survival outcomes," said Fernando Rivera, M.D., Medical Oncology Department, Hospital Universitario Marques de Valdecilla, Santander, Spain, and a lead investigator in the study. "These data suggest that a front-line treatment strategy with panitumumab in combination with FOLFOX may offer clinical benefit in patients with wild-type RAS metastatic colorectal cancer compared to bevacizumab-based regimens in this treatment setting."
News For AMGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 30, 2015
09:02 EDTAMGNAmgen says FDA grants priority review for Kyprolis sNDA
Subscribe for More Information
March 26, 2015
06:45 EDTAMGNBiotech valuation concerns 'misguided,' says Piper Jaffray
Subscribe for More Information
March 24, 2015
09:10 EDTAMGNDako announces collaboration agreement with Amgen
Dako, an Agilent Technologies (A) company, announced a new Master Collaboration Agreement with Amgen (AMGN). The expanded collaboration will allow both companies to benefit from knowledge-sharing within the field of drug-diagnostic research and development in general, and in relation to companion diagnostic products in particular. The financial details of the agreement were not disclosed.
March 23, 2015
12:10 EDTAMGNTeva migraine drug data positive for Amgen, says Piper Jaffray
Piper Jaffray said the "positive" trial data Teva (TEVA) reported for its anti-CGRP antibody in migraines is another important validation for the class of drugs that is also being worked on by Amgen (AMGN), Eli Lilly (LLY) and Alder Biopharmaceuticals (ALDR). The firm said it thinks Amgen is one of the leaders in CGRP antibody space and reiterated its Overweight rating and $187 price target on Amgen shares.
09:03 EDTAMGNLeerink analysts hold a meeting with a conference call hookup
Subscribe for More Information
March 20, 2015
09:06 EDTAMGNAmgen submits application for marketing approval for RepathaTM in Japan
Subscribe for More Information
07:41 EDTAMGNAmerican Academy of Dermatology to hold annual meeting
Subscribe for More Information
March 19, 2015
15:55 EDTAMGNAmgen injunction bid for Neupogen biosimilar denied, Reuters reports
Subscribe for More Information
15:13 EDTAMGNAmgen denied preliminary injunction for biologics against Novartis, Reuters says

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use